Novocure Is Maintained at In-Line by Evercore ISI Group
NovoCure Analyst Ratings
Evercore Maintains Novocure(NVCR.US) With Hold Rating, Cuts Target Price to $18
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $40
Wells Fargo Remains a Buy on NovoCure (NVCR)
NovoCure Analyst Ratings
H.C. Wainwright Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $24
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
NovoCure Analyst Ratings
NovoCure Analyst Ratings
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
NovoCure Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
NovoCure Analyst Ratings
NovoCure Analyst Ratings
NovoCure's TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed With Raised Price Target
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
NovoCure Analyst Ratings